Regulation of PI3K signaling in cancer metabolism and PI3K-targeting therapy

被引:10
作者
Han, Beinan
Lin, Xiaorong [1 ]
Hu, Hai [2 ]
机构
[1] Shantou Cent Hosp, Diag & Treatment Ctr Breast Dis, Shantou 515000, Peoples R China
[2] Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp Inst Basic Med & Canc IBMC, Hangzhou 310022, Peoples R China
来源
TRANSLATIONAL BREAST CANCER RESEARCH | 2024年 / 5卷
关键词
Phosphatidylinositol-3-kinase (PI3K); cancer; metabolism; target therapy; PI3K inhibitor; ALPELISIB PLUS FULVESTRANT; ADVANCED BREAST-CANCER; PHASE-III; NUCLEOTIDE-METABOLISM; PILARALISIB SAR245408; LIPID-METABOLISM; DOSE-ESCALATION; C-MYC; INHIBITOR; PHOSPHORYLATION;
D O I
10.21037/tbcr-24-29
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The phosphatidylinositol-3-kinase (PI3K) signaling plays a key role in various cellular functions and is frequently activated in cancer, making it an attractive therapeutic target. The PI3K signaling pathway influencing glucose metabolism, lipid synthesis, nucleotide production, and protein synthesis, all of which contribute to cancer cell proliferation and survival. It enhances glucose uptake through the activation of glucose transporters and glycolysis, while also promoting lipid synthesis via downstream factors like mTORC1. This pathway boosts nucleotide synthesis by regulating transcription factors like MYC, activating key enzymes for purine and pyrimidine production. Additionally, due to its essential role in cancer cell growth, the PI3K pathway is a key target for anticancer therapies. However, treatment using PI3K inhibitors alone has limitations, including drug resistance and significant side effects such as hyperglycemia, fatigue, and liver dysfunction. Clinical trials have led to the development of isoform-specific PI3K inhibitors to reduce toxicity. Combining PI3K inhibitors with other treatments, such as hormone therapy or surgery, may improve efficacy and minimize side effects. Further research is needed to fully understand the mechanisms of PI3K inhibitors and improve individualized treatment approaches. In this review, we introduce the characteristic of three classes of PI3Ks, discuss the regulation of cancer metabolism including the control of glucose uptake, glycolysis, de novo lipid synthesis, nucleotide synthesis and protein synthesis, and review the current statuses of different PI3K inhibitors therapy.
引用
收藏
页数:15
相关论文
共 110 条
[61]   Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells [J].
Mannava, Sudha ;
Grachtchouk, Vladimir ;
Wheeler, Linda J. ;
Im, Michael ;
Zhuang, Dazhong ;
Slavina, Elena G. ;
Mathews, Christopher K. ;
Shewach, Donna S. ;
Nikiforov, Mikhail A. .
CELL CYCLE, 2008, 7 (15) :2392-2400
[62]   Class II PI3Ks at the Intersection between Signal Transduction and Membrane Trafficking [J].
Margaria, Jean Piero ;
Ratto, Edoardo ;
Gozzelino, Luca ;
Li, Huayi ;
Hirsch, Emilio .
BIOMOLECULES, 2019, 9 (03)
[63]   Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma [J].
Matulonis, Ursula ;
Vergote, Ignace ;
Backes, Floor ;
Martin, Lainie P. ;
McMeekin, Scott ;
Birrer, Michael ;
Campana, Frank ;
Xu, Yi ;
Egile, Coumaran ;
Ghamande, Sharad .
GYNECOLOGIC ONCOLOGY, 2015, 136 (02) :246-253
[64]   Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941 [J].
Mehraj, Umar ;
Wani, Nissar Ahmad ;
Hamid, Abid ;
Alkhanani, Mustfa ;
Almilaibary, Abdullah ;
Mir, Manzoor Ahmad .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[65]   Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth [J].
Mishra, Rosalin ;
Yuan, Long ;
Patel, Hima ;
Karve, Aniruddha S. ;
Zhu, Haizhou ;
White, Aaron ;
Alanazi, Samar ;
Desai, Pankaj ;
Merino, Edward J. ;
Garrett, Joan T. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (04) :1-16
[66]   mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation [J].
Morita, Masahiro ;
Gravel, Simon-Pierre ;
Chenard, Valerie ;
Sikstrom, Kristina ;
Zheng, Liang ;
Alain, Tommy ;
Gandin, Valentina ;
Avizonis, Daina ;
Arguello, Meztli ;
Zakaria, Chadi ;
McLaughlan, Shannon ;
Nouet, Yann ;
Pause, Arnim ;
Pollak, Michael ;
Gottlieb, Eyal ;
Larsson, Ola ;
St-Pierre, Julie ;
Topisirovic, Ivan ;
Sonenberg, Nahum .
CELL METABOLISM, 2013, 18 (05) :698-711
[67]   The SLC2 (GLUT) family of membrane transporters [J].
Mueckler, Mike ;
Thorens, Bernard .
MOLECULAR ASPECTS OF MEDICINE, 2013, 34 (2-3) :121-138
[68]   Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor [J].
Munakata, Wataru ;
Tobinai, Kensei .
LANCET HAEMATOLOGY, 2018, 5 (04) :E134-E135
[69]   Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]midazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity [J].
Ndubaku, Chudi O. ;
Heffron, Timothy P. ;
Staben, Steven T. ;
Baumgardner, Matthew ;
Blaquiere, Nicole ;
Bradley, Erin ;
Bull, Richard ;
Do, Steven ;
Dotson, Jennafer ;
Dudley, Danette ;
Edgar, Kyle A. ;
Friedman, Lori S. ;
Goldsmith, Richard ;
Heald, Robert A. ;
Kolesnikov, Aleksandr ;
Lee, Leslie ;
Lewis, Cristina ;
Nannini, Michelle ;
Nonomiya, Jim ;
Pang, Jodie ;
Price, Steve ;
Prior, Wei Wei ;
Salphati, Laurent ;
Sideris, Steve ;
Wallin, Jeffery J. ;
Wang, Lan ;
Wei, BinQing ;
Sampath, Deepak ;
Olivero, Alan G. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) :4597-4610
[70]   Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia [J].
Niu, Yi ;
Lin, Ziyou ;
Wan, Arabella ;
Sun, Lei ;
Yan, Shijia ;
Liang, Heng ;
Zhan, Siyue ;
Chen, Dongshi ;
Bu, Xianzhang ;
Liu, Peiqing ;
Chen, Ceshi ;
He, Weiling ;
Lu, Xiongbin ;
Wan, Guohui .
HEPATOLOGY, 2021, 74 (03) :1461-1479